Project Grant R15AG092927
Award Date
5/15/25
Completion Date
4/30/28
Dollars Obligated
$514K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), aims to develop novel lipid nanoparticle (LNP) formulations for delivering nucleic acid-based therapeutics to the brain for treating Alzheimer's disease (AD). The $835,417 award will support research to synthesize BBB-crossing lipids, formulate LNP-RNA constructs, elucidate their trafficking across the blood-brain barrier, engineer siRNA and mRNA sequences to modulate APOE...
This Project Grant award for $506,451 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) aims to develop an effective targeted delivery system for small interfering RNA (siRNA) therapeutics to mitigate neuroinflammatory diseases, including Alzheimer's disease. The project leverages the awardee's 3P Biotechnologies, Inc.'s expertise in exosome engineering, drug delivery, and siRNA therapeutics. The key products or services to be delivered under this award...
The National Institute on Aging (NIA) awarded a $295,000 Project Grant (CFDA 93.866 - Aging Research) to Florida International University to develop biotherapeutic nanogels for the treatment of Alzheimer's disease. The goal is to create a novel nanogel system that can effectively cross the blood-brain barrier, inhibit amyloid-beta aggregation, and reduce oxidative stress and neuroinflammation associated with Alzheimer's. The project will focus on improving the nanogel formulation for enhanced...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
This Project Grant award of $751,442 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to optimize and preclinically evaluate a brain-permeable CRISPR-based therapy to edit the APOE4 gene and convert it to the benign APOE3 variant in Alzheimer's disease (AD) models. The key products and services to be delivered include: Optimizing the CRISPR delivery platform using microfluidic synthetic exosomes (SE) to enhance plasma half-life and blood-brain barrier...
The National Institute on Aging (NIA) awarded a $1,512,892 Project Grant under the Aging Research program (CFDA 93.866) to 3P Biotechnologies, Inc. to develop a targeted nanoformulation delivery system for the bioactive curcuminoids, curcumin and bisdemethoxycurcumin, to treat Alzheimer's disease (AD). The Phase I project aims to optimize exosome-based formulations of these compounds and assess their biodistribution and toxicity in mice, as well as determine the efficacy of folic...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
The National Institute on Aging (NIA), under its Aging Research Federal Grant Program (CFDA 93.866), awarded a $154,748 Project Grant to Brigham & Women's Hospital Inc. to develop an ultrasensitive blood-based diagnostic tool for accurately detecting and monitoring Alzheimer's disease (AD). The project aims to engineer a diagnostic pipeline that leverages extracellular vesicles (EVs) and single molecule detection technology to quantify low-abundance AD protein biomarkers, particularly...
This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...